avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2013-0-3-25-37avk-191Research ArticleПРИЕМ ВЕДЕТ...ПАЦИЕНТ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ НА АМБУЛАТОРНОМ ПРИЁМЕ У ТЕРАПЕВТАПАЦИЕНТ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ НА АМБУЛАТОРНОМ ПРИЁМЕ У ТЕРАПЕВТАВёрткинА. Л.ВёрткинА. Л.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

skotnikov.as@mail.ruПрохоровичЕ. А.ПрохоровичЕ. А.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

skotnikov.as@mail.ruСкотниковА. С.СкотниковА. С.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

skotnikov.as@mail.ruАлгиянЕ. А.АлгиянЕ. А.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

skotnikov.as@mail.ruАлексеевМ. А.АлексеевМ. А.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

skotnikov.as@mail.ruАбдулаеваА. У.АбдулаеваА. У.

кафедра терапии, клинической фармакологии и скорой медицинской помощи

кафедра терапии, клинической фармакологии и скорой медицинской помощи

skotnikov.as@mail.ruГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова»РоссияГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова»Russian Federation201328062013032537Copyright © Вёрткин А.Л., Прохорович Е.А., Скотников А.С., Алгиян Е.А., Алексеев М.А., Абдулаева А.У., 20132013Вёрткин А.Л., Прохорович Е.А., Скотников А.С., Алгиян Е.А., Алексеев М.А., Абдулаева А.У.Вёрткин А.Л., Прохорович Е.А., Скотников А.С., Алгиян Е.А., Алексеев М.А., Абдулаева А.У.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/191

Клинические наблюдения амбулаторных пациентов и умерших больных с МА, а также выполнение Рекомендаций Российского кардиологического общества и Европейского общества кардиологов по ведению больных с ФП стали предметом обсуждения на Московской окружной конференции терапевтов и онлайн-трансляции. Все участники в интерактивном формате обсуждали вопросы профилактики тромботических осложнений (в частности инсульта) с помощью современной антитромботической терапии с использованием новых пероральных антикоагулянтов.

Clinical observation of outpatients and deceased patients with atrial fibrillation, as well as implementing the Recommendations of the Russian Society of Cardiology and the European Society of Cardiology for the management of patients with atrial fibrillation were discussed during Moscow district therapists’ conference and online broadcast. All participants in the interactive format considered prevention of thrombotic events (such as strokes) by means of modern antithrombotic therapy using novel oral anticoagulants.

фибрилляция предсердийтромботические осложненияинсультострый инфаркт миокардаривароксабанварфаринантитромботическая терапияatrial fibrillationthrombotic complicationsstrokeacute myocardial infarctionrivaroxaban warfarinantithrombotic therapyкомпания «Байер»ReferencesAngeli F., Reboldi G, Garofoli M. et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis // Curr. Cardiol. Rep. 2012. Vol. 14 (5). P. 601–610.Angeli F., Reboldi G, Garofoli M. et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis // Curr. Cardiol. Rep. 2012. Vol. 14 (5). P. 601–610.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials // Arch Intern Med. 1994. Vol. 154 (13). P. 1449–1457.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials // Arch Intern Med. 1994. Vol. 154 (13). P. 1449–1457.Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. Vol. 33 (21). P. 2719–2747. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24.Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. Vol. 33 (21). P. 2719–2747. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24.Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet. 2006. Vol. 367 (9526). P. 1903–1912.Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet. 2006. Vol. 367 (9526). P. 1903–1912.Crijns H.J. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say // Drugs. 2005. Vol. 65 (12). P. 1651–1667.Crijns H.J. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say // Drugs. 2005. Vol. 65 (12). P. 1651–1667.Fang M.C., Go A.S., Chang Y., Borowsky L.H. et al. Warfarin discontinuation after starting warfarin for atrial fibrillation // Circ Cardiovasc Qual Outcomes. 2010. Vol. 3 (6). P. 624–631.Fang M.C., Go A.S., Chang Y., Borowsky L.H. et al. Warfarin discontinuation after starting warfarin for atrial fibrillation // Circ Cardiovasc Qual Outcomes. 2010. Vol. 3 (6). P. 624–631.Fox C.S., Parise H., D’Agostino R.B.Sr. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring // JAMA. 2004. Vol. 291. P. 2851–2855.Fox C.S., Parise H., D’Agostino R.B.Sr. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring // JAMA. 2004. Vol. 291. P. 2851–2855.Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. 2010. Vol. 31. P. 967–975.Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. 2010. Vol. 31. P. 967–975.Fuster V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial brillation // J. Am. Coll. Cardiol. 2001. Vol. 38. P. 1231–1266.Fuster V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial brillation // J. Am. Coll. Cardiol. 2001. Vol. 38. P. 1231–1266.Goldstein L.B., Akin D.R., Samsa G.P. et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices // Stroke. 1995. Vol. 26 (9). P. 1607–1615.Goldstein L.B., Akin D.R., Samsa G.P. et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices // Stroke. 1995. Vol. 26 (9). P. 1607–1615.Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Hart R.G., Halperin J.L. Atrial fibrillation and stroke: Concepts and controversies // Stroke. 2001. Vol. 32. P. 803–808.Hart R.G., Halperin J.L. Atrial fibrillation and stroke: Concepts and controversies // Stroke. 2001. Vol. 32. P. 803–808.Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators // Stroke. 1999. Vol. 30 (6). P. 1223–1229.Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators // Stroke. 1999. Vol. 30 (6). P. 1223–1229.Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Engl. J. Med. 2003. Vol. 349 (11). P. 1019–1026.Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Engl. J. Med. 2003. Vol. 349 (11). P. 1019–1026.Jan Heeringa, Deirdre A.M. van der Kuip et al. // European Heart Journal. 2006. Vol. 27. Р. 949–953. doi:10.1093/eurheartj/ehi825.Jan Heeringa, Deirdre A.M. van der Kuip et al. // European Heart Journal. 2006. Vol. 27. Р. 949–953. doi:10.1093/eurheartj/ehi825.Kirchhof P., Auricchio A., Bax J. Outcome parameters for trials in atrial fibrillation: executive summary // Eur .Heart J. 2007. Vol. 28 (22). P. 2803–2817.Kirchhof P., Auricchio A., Bax J. Outcome parameters for trials in atrial fibrillation: executive summary // Eur .Heart J. 2007. Vol. 28 (22). P. 2803–2817.Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. 2010. Vol. 137 (2). P. 263–272.Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. 2010. Vol. 137 (2). P. 263–272.Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation. 2004. Vol. 110 (9). P. 1042–1046. Epub 2004 Aug 16.Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation. 2004. Vol. 110 (9). P. 1042–1046. Epub 2004 Aug 16.Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // BMJ Open. 2012. Vol. 2. e001592.Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // BMJ Open. 2012. Vol. 2. e001592.Nieuwlaat R. et al. The Euro Heart Survey on Atrial Fibrillation // Am. Heart J. 2007. Vol. 153. P. 1006–1012.Nieuwlaat R. et al. The Euro Heart Survey on Atrial Fibrillation // Am. Heart J. 2007. Vol. 153. P. 1006–1012.Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. 2005. Vol. 26. P. 2422–2434.Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. 2005. Vol. 26. P. 2422–2434.Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011 Vol. 365(10). P. 883–891.Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011 Vol. 365(10). P. 883–891.Pisters R., Lane D.A, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest. 2010. Vol. 138 (5). P. 1093–1100.Pisters R., Lane D.A, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest. 2010. Vol. 138 (5). P. 1093–1100.Stöllberger C., Schneider B., Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? // Chest. 2003. Vol. 124 (6). P. 2356–2362.Stöllberger C., Schneider B., Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? // Chest. 2003. Vol. 124 (6). P. 2356–2362.Sun Y., Hu D. The link between diabetes and atrial fibrillation: cause or correlation? // J. Cardiovasc. Dis. 2010. Vol. 1. P. 10–11.Sun Y., Hu D. The link between diabetes and atrial fibrillation: cause or correlation? // J. Cardiovasc. Dis. 2010. Vol. 1. P. 10–11.Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrilla-tion: a systematic review // Am. J. Med. 2006. Vol. 119 (448). e1–e19.Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrilla-tion: a systematic review // Am. J. Med. 2006. Vol. 119 (448). e1–e19.Tonje A. Aksnes and Sverre E. Kjeldsen. A link between hypertension and atrial fibrillation: methods of treatment and prevention // Current Vascular Pharmacology. 2010. Vol. 6. P. 769–774.Tonje A. Aksnes and Sverre E. Kjeldsen. A link between hypertension and atrial fibrillation: methods of treatment and prevention // Current Vascular Pharmacology. 2010. Vol. 6. P. 769–774.Vidaillet H., Granada J.F., Chyou P. et al. A population-based study of mortality among patients with atrial fibrillation or flutter // Am. J. Med. 2002. Vol. 113 (5). P. 365-370.Vidaillet H., Granada J.F., Chyou P. et al. A population-based study of mortality among patients with atrial fibrillation or flutter // Am. J. Med. 2002. Vol. 113 (5). P. 365-370.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited // Lancet. 2009. Vol. 373. P. 155–166.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited // Lancet. 2009. Vol. 373. P. 155–166.

The authors declare that there are no conflicts of interest present.